NASDAQ · Biotechnology

Entasis Therapeutics Holdings Inc. (ETTX) Stock

$2.19 -0.45% NASDAQ: ETTX Healthcare

Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions.

Valuation

MetricValue
Price$2.19
Market Cap$0
P/E Ratio-2.19
P/B Ratio3.32
P/S Ratio0.00
EPS (TTM)$-1.00
52-Week High—
52-Week Low—
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-151.61%
ROA-114.63%
ROCE-151.03%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20172018201920202021
Revenue$0$5.0M$7.0M$0$0
Operating Profit$-31.0M$-38.0M$-47.0M$-54.0M$-47.0M
Net Profit$-30.0M$-33.0M$-44.0M$-50.0M$-47.0M
EPS$-8.05$-9.64$-3.33$-2.10$-1.00
Op Margin—-764.1%-670.5%——

Balance Sheet (USD)

Metric20172018201920202021
Total Assets$59.0M$89.0M$51.0M$62.0M$41.0M
Total Liabilities$115.0M$6.0M$9.0M$9.0M$10.0M
Cash$55.0M$49.0M$16.0M$53.0M$32.0M
Borrowings$0$0$2.0M$1.0M$0

Latest News

Eala stuns Osaka to book Washington final against Pegula AFP · Aug 2, 2026 OpenAI, Anthropic hacking models breached companies after escaping tests Investing.com · Aug 2, 2026 The 401(k) Roth Conversion Math That Saves $41,000 in Taxes Before RMDs Kick In 24/7 Wall St. · Aug 2, 2026 Elon Musk's Tesla Delivered 480,126 Vehicles in Q2, a 25% Jump From a Year Ago Motley Fool · Aug 2, 2026 Vincent Pastore, who played 'Big Pussy' on 'The Sopranos,' dead at 80 AFP · Aug 2, 2026

Cash Flow (USD)

Metric20172018201920202021
Operating Cash Flow$-27.0M$-36.0M$-45.0M$-45.0M$-43.0M
Investing Cash Flow$-1.0M$-36.0M$11.0M$25.0M$0
Financing Cash Flow$56.0M$66.0M$0$58.0M$22.0M
Net Cash Flow$29.0M$-6.0M$-33.0M$37.0M$-21.0M
Free Cash Flow$-27.0M$-36.0M$-45.0M$-45.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA0.69
FCF Yield—
Quick Ratio4.10
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to advance its portfolio. A licensing and collaboration agreement is in place with Zai Lab (Shanghai) Co., Ltd. for the continued development of durlobactam and SUL-DUR. Additionally, they have a collaborative arrangement with the Global Antibiotic Research and Development Partnership for the development and subsequent commercialization of Zoliflodacin. Established in 2015, Entasis Therapeutics Holdings Inc. maintains its corporate headquarters in Waltham, Massachusetts, and functions as a subsidiary of Innoviva, Inc.

the stock is valued at a price-to-earnings (P/E) ratio of -2.19, price-to-book of 3.32, price-to-sales of 0.00.

On profitability, Entasis Therapeutics Holdings Inc. generates a return on equity (ROE) of -151.61%, return on capital employed of -151.03%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: innovivaspecialtytherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides